The contrast agent Isovue, according to its manufacturer, is said to be a safe and effective nonionic contrast medium well established with U.S. clinical experience since 1986. Worldwide, more than 250 million doses of iopamidol have been administered.

One IT challenge facing medical facilities is the ability to receive diagnostic imaging studies, associated medical information and full patient demographics from outside its usual network to be read or considered by its third-party diagnosticians or specialists.